Global Ulcerative Colitis Treatment Market is Segmented By Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis), By Drug Class (Immunosuppressant, Anti-Inflammatory Drugs, Anti-TNF biologics, Calcineurin Inhibitors, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Size
The Global Ulcerative Colitis Treatment Market reached US$ 6.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 11.1 billion by 2031. The global ulcerative colitis treatment market is expected to exhibit a CAGR of 6.3% during the forecast period (2024-2031).
The growing number of inflammatory bowel diseases including ulcerative colitis, increasing research activities, rising number of product approvals, and market developments such as mergers, acquisitions, collaborations, and product introductions are among the primary factors expected to drive the global ulcerative colitis treatment market growth in the forecast period.
Market Scope
| Metrics | Details |
| CAGR | 6.3% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Drug Class, Route of Administration, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To Know More Insights - Download Sample
Market Dynamics
Increasing Market Developments Drive The Growth Of The Ulcerative Colitis Treatment Market
The increasing market developments in the ulcerative colitis treatment market are expected to boost the market growth in the forecast period. For instnace, in March 2022, Pfizer, an American global pharmaceutical and biotechnology company acquired Arena Pharmaceuticals, an American biopharmaceutical corporation.
With this acquisition, the corporation sought to connect the outstanding pipeline and background of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing domain, aiding additional motives of improvement increase to transform the lives of patients with immuno-inflammatory illness.
Moreover, in July 2022, Athos Therapeutics, a clinical-stage biotechnology corporation disclosed strategies for research alliance with Lahey Hospital and Medical Center in Burlington, Massachusetts for the designing of precision medicine in IBD and ulcerative colitis.
The Increase in Research Activities is Expected to Present the Global Ulcerative Colitis Treatment Market with Growth Opportunities
The increasing research activities are presenting the global market with prospective growth opportunities. For instnace, in June 2021, Takeda Pharmaceutical Company Limited, a Japanese multinational pharmaceutical company began a phase III clinical investigation to evaluate the effectiveness and safety of intravenous (IV) Vedolizumab in Japanese individuals with moderate to extreme ulcerative colitis. The trial is anticipated to be concluded by September 2024.
The Presence of Stringent Regulatory Bodies is Estimated to Hamper the Global Ulcerative Colitis Treatment Market During the Forecast Period
The presence of stringent regulatory bodies for the approval of newly developed drugs for ulcerative colitis is hampering the global market growth in the forecast period. For instnace, the major regulatory bodies supervising the authorization and commercialization of ulcerative treatment drugs include the United States Food and Drug Administration (USFDA) and the European Medicines Agency, an agency of the European Union in charge of the evaluation and supervision of pharmaceutical products in European Union.
Market Segment Analysis
The global ulcerative colitis treatment market is segmented based on type, drug class, route of administration, distribution channel, and region.
The Immunosuppressant Drug Class is Estimated to Dominate the Global Ulcerative Colitis Treatment Market
Owing to the increasing product introductions the immunosuppressant drug class segment is estimated to dominate the global ulcerative colitis treatment market holding around 39.6% of the global market. For instance, in November 2021, Bristol Myers Squibb obtained marketing authorization from the European Commission for Zeposia (ozanimod) an immunosuppressant for the therapy of adults with intermediate to extremely active ulcerative colitis (UC) who have had an insufficient reaction, lost response, or are intolerant to either orthodox therapy or a biologic agent.
Source: DataM Intelligence Analysis (2023)
Top of Form
Market Geographical Share
North America is Estimated to hold Approximately 38.8% of the Market Share by 2030, Owing to the Increasing Cases of Chronic Conditions
Owing to the high prevalence of inflammatory bowel diseases in America, the North American region is estimated to hold around 38.8% of the global market by 2030. For instnace, according to the statistics published by the Crohn's & Colitis Foundation, roughly 1.6 million Americans suffer from inflammatory bowel disease, including ulcerative colitis.
Furthermore, increasing investigations for new drug developments by the US-based key market players are expected to boost regional market growth. For instnace, in April 2022, Pfizer, an American multinational biopharmaceutical company, informed the promising topline conclusions from a Phase 3 investigation of stasimon, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator being designed for the treatment of intermediate to extremely active ulcerative colitis (UC).
Source: DataM Intelligence Analysis (2023)
Market Companies
The major global players in the ulcerative colitis treatment market include Abbott Laboratories, Ajinomoto, AstraZeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi, among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is thought to hold a moderate influence on the global ulcerative colitis treatment market, as there is a low prevalence of ulcerative colitis and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of fundamental materials are expected to have a slight impact on the global ulcerative colitis treatment market growth in the forecast period.
By Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
By Drug Class
- Immunosuppressant
- Anti-Inflammatory Drugs
- Anti-TNF biologics
- Calcineurin Inhibitors
- Other
By Route of Administration
- Oral
- Injectables
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- In December 2021, Eisai Co., Ltd., a Japanese pharmaceutical corporation, and Gilead Sciences, Inc., an American biopharmaceutical corporation agreed to jointly commercialize and distribute filgotinib, an oral, JAK1 preferential inhibitor for indications of ulcerative colitis and Crohn's disease in Asia (Singapore, Hong Kong, South Korea, and Taiwan).
- In October 2022, the National Institute for Health and Care Excellence (NICE) advised Bristol Myers Squibb's (BMS) Zeposia (ozanimod) for the treatment of adults with moderate-to-severe active ulcerative colitis (UC).
- In October 2021, First Wave Biopharma Inc., a clinical-stage biopharmaceutical corporation dosed the first patient in a Phase 2b clinical trial studying a topical formulation of niclosamide (FW-UP) as a potential therapy for individuals with ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).
Why Purchase the Report?
- To visualize the global ulcerative colitis treatment market segmentation based on type, drug class, route of administration distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of ulcerative colitis treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Type mapping available in excel consisting of key types of all the major players.
The global ulcerative colitis treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
